Microbial Metabolite

在健康个体中，牛磺脱氧胆酸盐的中位血浆浓度为 33.9 nM[1]。牛磺脱氧胆酸盐的 IC50 为 170 µM，可抑制 N-3H-甲基东莨菪碱与乙酰胆碱 M3 毒蕈碱受体结合的能力[1]。牛磺脱氧胆酸盐（0.05–1.00 mM；1–6 天）促进肠上皮细胞的生长[2]。牛磺脱氧胆酸盐（0.05–1.00 mM；24 小时）可增强 IEC-6 细胞中 c-myc 蛋白和 mRNA 的产生，并导致细胞周期 G1 期浓度显着下降和 S 期浓度增加[2]。

---

IEC-6或Caco-2细胞用不同浓度的Taurodeoxychloic Acid/牛磺脱氧胆酸（0.05至1 mmol/L）处理，并测定增殖情况。通过DNA断裂分析和核染色来测量细胞凋亡。用碘化丙啶流式细胞术测定细胞相。通过Northern和Western印迹分析确定C-myc表达，特异性C-myc反义抑制C-myc功能。
结果：细胞结构无变化。未诱导细胞凋亡。暴露于牛磺脱氧胆酸六天后，IEC-6细胞增殖显著增加。流式细胞术显示细胞周期的S期浓度显著增加，G1期浓度显著降低。牛磺脱氧胆酸还可增加c-myc蛋白和mRNA的表达，抑制c-myc功能可阻止牛磺脱氧胆碱诱导的细胞增殖。
结论：暴露于生理浓度的胆汁盐牛磺脱氧胆酸会增加肠上皮细胞的增殖。这种作用至少部分是通过c-myc依赖机制介导的。胆汁盐对肠粘膜有有益的影响[1]。

牛磺脱氧胆酸盐（0.5 mg/kg；静脉注射；一次）可保护脓毒症 C57BL/6N 小鼠，但不能保护 TGR5 KO 小鼠[1]。

---

TDCA/牛磺脱氧胆酸对脓毒症小鼠具有保护作用[1]
当我们在注射LPS后30分钟或24小时静脉注射牛磺脱氧胆酸/TDCA（0.5mg/kg）时，分别有80%和50%的小鼠存活（图1A，p<0.05）。0.4 mg/kg的TDCA剂量足以获得这种效果（图S1A）。此外，在盲肠结扎和穿刺后2小时输注TDCA时，70%的小鼠存活（CLP，图1B，p<0.05）。静脉输注（1 mg/kg）后，TDCA的血浆Cmax（=502 ng/ml）约为之前报告的50%溶血浓度（420μg/ml）的1/1000（图S1B），比体外细胞毒性剂量低约1/1000（33）。TDCA在脓毒症下对TGR5 KO小鼠没有保护作用（图S1C）。

TDCA/牛磺脱氧胆酸可减少脓毒症小鼠的肝肾损伤（图1C、D和图S2）。肾脏的H&E染色显示，注射LPS的小鼠表现出明显的小管空泡变性（图1C中的箭头）。TDCA输注几乎完全改善了LPS诱导的肾脏损伤（图1C）。肾小球毛细血管环基底膜和肾小管上皮上的粘多糖也用PAS染色（图1C右栏中的箭头）。LPS+PBS组刷状边界的丧失非常显著（箭头），TDCA输注后显著恢复（图1C中的箭头）。TDCA输注使LPS注射后4小时的肾功能、肝功能和低血压恢复正常（图1D、E、图S2）。在LPS注射和CLP模型中，TDCA也显著抑制了TNF-α、MCP-1、IL-6和IL-1β等细胞因子的产生（图1F-H，图S3）。

---

牛磺脱氧胆酸/TDCA可增加CD11B+Gr1hi细胞的表型[1]
如前所述（34），脓毒症小鼠在注射LPS后48小时和CLP后72小时的脾细胞数量减少（图2A、图S4）。然而，在LPS注射后48小时，LPS+TDCA/牛磺酸组的脾细胞总数显著增加，CLP+TDCA组在72小时时脾细胞总数也显著增加。CD11b+Gr1+细胞在LPS+TDCA组和CLP+TTCA组中均增加（图2B、C、图S4、S5）。TDCA治疗没有增加T细胞或CD11c+细胞的数量（图S6）。CD4+FoxP3+Treg细胞的数量或这些细胞上CTLA4的表达没有显著变化（图S7）。

---

胆汁酸（BA）通过与多种受体相互作用来控制代谢和炎症。在这里，我们报告静脉注射牛磺脱氧胆酸盐（TDCA）可降低血清促炎细胞因子，使低血压正常化，保护肾脏免受损伤，并延长脓毒症期间小鼠的存活时间牛磺脱氧胆酸/TDCA增加了脓毒症小鼠脾脏中粒细胞-髓系衍生抑制细胞（MDSCLT）的数量，这些细胞与未经TDCA治疗的MDSC不同。FACS分选的MDSCLT细胞抑制T细胞增殖，并在过继转移时比MDSCL更好地提供对败血症的保护。蛋白质组学分析表明，TDCA控制着MDSCLT免疫蛋白质组的染色质沉默、选择性剪接和翻译，从而增加了抑瘤素、乳铁蛋白和CD244等抗炎分子的表达。TDCA还能降低促炎分子如中性粒细胞弹性蛋白酶的表达。这些发现表明，TDCA在全球范围内编辑蛋白质组，以增加MDSCLT细胞的数量，并影响其免疫调节功能，以解决败血症期间的全身炎症。

细胞增殖测定[2]
细胞类型： IEC-6 和 caco-2 细胞
测试浓度： 0、0.05、0.50 和 1.00 mM
孵育时间：1、2、4和6天
实验结果：以剂量依赖性方式显着刺激肠上皮细胞增殖。

---

细胞周期分析[2]
细胞类型： IEC-6 细胞
测试浓度： 0、0.05、0.50 和 1.00 mM
孵育时间： 24 h
实验结果： S期细胞显着增加，G1期细胞减少。

---

蛋白质印迹分析[2]
细胞类型： IEC-6 细胞
测试浓度： 0.5 mM
孵育持续时间：1 和 6 天
实验结果：c-myc 蛋白表达显着增加。

---

T细胞增殖试验[1]
使用MACS和泛T细胞分离试剂盒从小鼠脾脏中纯化T细胞。在含有10%热灭活FBS和2mM谷氨酰胺的RPMI 1640培养基中，用1μg/ml抗CD3和10μg/ml抗CD28抗体刺激总共2×105个正常脾脏T细胞。将来自LPS+PBS组或LPS+牛磺脱氧胆酸/TDCA组的FACS分选的CD11b+Gr1hi细胞与T细胞在96孔平底板中以4×104/孔（E:T=1:5）的终浓度混合，并在37°C下在加湿的5%CO2气氛中培养96小时。不含CD11b+Gr1hi细胞培养的T细胞作为阴性对照。用1μCi[3H]甲基胸苷脉冲细胞18小时。用Filtermate Harvester收获细胞，用MicroBeta平板计数器测量同位素掺入。数据表示为每分钟计数（cpm）±平均值标准误差（SEM）。

---

CD11b+Gr1hi细胞的过继转移[1]
在B6小鼠腹腔注射LPS后30分钟，通过尾静脉静脉输注PBS或牛磺脱氧胆酸/TDCA。LPS注射后24小时，从脾脏中分离出细胞。在冰上将细胞在阻断缓冲液中孵育30分钟后，用生物素偶联的抗小鼠Gr1抗体（克隆RB6-8C5）对细胞进行染色，然后在4°C下用抗生物素微珠染色15分钟。用MACS缓冲液（0.5%BSA和2 mM EDTA的PBS溶液）洗涤后，使用LS柱对细胞进行阳性选择。用MACS预分选的Gr1+细胞进一步用抗CD11b（与PE结合）和F4/80（与FITC结合）的单克隆抗体染色，用于FACS分选。使用流式细胞仪对CD11b+Gr1hi F4/80int细胞进行分选。共1×105个细胞通过尾静脉注射到B6小鼠体内。受体小鼠在过继转移前24小时腹腔注射LPS。

---

细胞裂解物的溶液内消化[1]
CD11b+Gr1hi细胞是从2组小鼠（LPS+PBS和LPS+TDCA/牛磺脱氧胆酸）中分选出来的FACS。使用8M尿素缓冲液制备FACS分选的CD11b+Gr1hi脾细胞的裂解物，并通过BCA测定法测定蛋白质浓度。将二硫苏糖醇加入裂解物（3 mM）中，在室温下孵育1小时。将细胞裂解物与碘乙酰胺（5 mM）混合，在暗室中孵育1 h。将一份裂解物与10份50 mM碳酸氢铵混合，在37°C下用胰蛋白酶（1/50×细胞裂解物的总蛋白量）消化16 h。随后使用宏旋柱（C-18）对样品进行脱盐。该柱预先用80%乙腈中的0.1%三氟乙酸（TFA）活化，随后用0.1%TFA水溶液（pH<3.0）平衡。将样品装入柱中，在室温下以1000×g离心2分钟。用0.1%TFA的水溶液洗涤柱，用0.1%TFA的80%乙腈溶液洗脱肽部分。肽样品用CentriVap®台式真空浓缩器干燥，肽浓度用BCA试剂盒测定。

---

iTRAQ标记肽[1]
使用用于相对和绝对定量的等压标签（iTRAQ）比较2组（LPS+PBS和LPS+TDCA/牛磺脱氧胆酸）CD11b+GR1hi细胞的蛋白质组。根据iTRAQ试剂盒的制造商方案，对每组100微克肽进行标记。简而言之，肽样品用500 mM碳酸氢三乙基铵（TEAB）缓冲液复溶，超声处理并涡旋。将用乙醇溶解的4-plex iTRAQ试剂加入肽样品中，并在室温下孵育1小时。向其中一份样品中加入3份0.05%TFA，并在常温下孵育30分钟。将iTRAQ标记的肽合并，随后使用CentriVap®台式真空浓缩器浓缩至300μl。然后将样品与1ml 50mM碳酸氢三乙基铵（TEAB）混合。

Animal/Disease Models: C57BL/6N mice, Lipopolysaccharides injection model of sepsis[1]
Doses: 0.5 mg/kg
Route of Administration: intravenous (iv) injection, 30 min or 24 h after LPS injection
Experimental Results: Improved the survival rate of mice with sepsis. diminished liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.

---

LPS injection model of sepsis [1]
The survival rate of the female mice was determined after i.p. injection of LPS (20 mg/kg), followed by the i.v. infusion of 200 μl of PBS or Taurodeoxychloic Acid/TDCA for 20 min (0.5 mg/kg, unless otherwise indicated) using a Medfusion 2001 system at 30 min (unless otherwise indicated) after LPS injection. For the protection assay using IL-10 KO mice, 5 mg/kg LPS were injected i.p. For the adoptive transfer experiments, B6 mice were injected i.v. with 100 μl of purified cells. The mice were treated with LPS 24 h prior to adoptive transfer, unless otherwise specified.

---

CLP-induced sepsis model [1]
Female B6 mice were anesthetized, and a small abdominal midline incision was made. The cecum was ligated below the ileocecal valve and punctured 3 times using a 23-gauge needle. The abdominal incision was closed with an auto-metal clip. The same procedure was applied to the sham-operated animals, with the exception of the ligation and puncture of the cecum. The mice were subsequently infused with 200 μl of PBS or Taurodeoxychloic Acid/TDCA i.v. at 2 h after CLP.

Taurodeoxycholate (TDCA) inhibits various inflammatory responses suggesting potential clinical application. However, the toxicity of TDCA has not been evaluated in detail in vivo. We investigated the acute toxicity and 4-week repeated-dose toxicity of TDCA following intravenous infusion under Good Laboratory Practice regulations. In the sighting study of acute toxicity, one of two rats (one male and one female) treated with 300 mg/kg TDCA died with hepatotoxicity, suggesting that the approximate 50% lethal dose of TDCA is 300 mg/kg. Edema and discoloration were observed at the injection sites of tails when rats were infused with 150 mg/kg or higher amount of TDCA once. In 4-week repeated-dose toxicity study, no treatment-related mortality or systemic changes in hematology and serum biochemistry, organ weights, gross pathology, or histopathology were observed. However, the tail injection site showed redness, discharge, hardening, and crust formation along with histopathological changes such as ulceration, edema, fibrosis, and thrombosis when rats were infused with 20 mg/kg TDCA. Taken together, TDCA induced no systemic toxicity or macroscopic lesions at the injection site at a dose of 10 mg/kg/day, which is 33 times higher than the median effective dose observed in a mouse sepsis model. These findings suggest that TDCA might have a favorable therapeutic index in clinical applications. [Drug Chem Toxicol. 2019 Jun 19:1-9.]

[1]. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984.

[2]. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135(2):215-21.

Sodium taurodeoxycholate hydrate is a cholanoid. It is functionally related to a taurodeoxycholic acid.

---

More than 2 million individuals worldwide suffer from sepsis on an annual basis. Because a plethora of pathogenic signaling pathways are simultaneously activated in septic patients, clinical trials targeting a single inflammatory mediator, coagulation factor or pro-inflammatory signal transducer have not shown significant survival benefits. In contrast to former strategies examining the blockade of pro-inflammatory pathways, targeting intrinsic immune regulatory mechanisms may be more effective for inhibiting the broad spectrum of pathways that are activated in sepsis. For these reasons, in vivo expansion of MDSCLT using a pharmacological dose of Taurodeoxychloic Acid/TDCA may be a plausible approach to inhibit the broad-spectrum pathogenesis exhibited in septic patients.[1]

---

This study shows that bile salt Taurodeoxychloic Acid/TDCA at least partially increases intestinal epithelial proliferation by regulating transcription of the proto-oncogene c-myc, which has been shown to play an important regulatory role during intestinal epithelial proliferation. This study further defines physiological roles for bile salts in the intestinal mucosa. Thus TDCA can affect cellular functions not just digestive functions in the intestinal mucosa and these effects occur via mediating expression of cell signaling and transcription factors. Further studies are needed to elucidate the role of bile salts during injury, repair and growth within the intestinal mucosa.[2]

C26H44NNAO6S

521.69

539.289

207737-97-1

Taurodeoxycholate sodium salt;1180-95-6;Taurodeoxycholic acid sodium hydrate;110026-03-4;Taurodeoxycholate-d6 sodium salt;2687960-92-3; 207737-97-1; 1180-95-6; Taurodeoxycholic acid sodium hydrate;110026-03-4;Taurodeoxycholic acid-d5;Taurodeoxycholic acid-d4 sodium;2410279-82-0;Taurodeoxycholic acid-d4;1332881-65-8

23702150

White to off-white solid powder

168ºC (dec.)(lit.)

4.462

144.37

4

7

7

36

864

10

C[C@H](CCC(=O)NCCS(=O)(=O)[O-])[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C.O.[Na+]

OLPIZAYYAVQETM-GGPRKOIFSA-M

InChI=1S/C26H45NO6S.Na.H2O/c1-16(4-9-24(30)27-12-13-34(31,32)33)20-7-8-21-19-6-5-17-14-18(28)10-11-25(17,2)22(19)15-23(29)26(20,21)3;;/h16-23,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33);;1H2/q;+1;/p-1/t16-,17-,18-,19+,20-,21+,22+,23+,25+,26-;;/m1../s1

sodium;2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate;hydrate

207737-97-1; Sodium taurodeoxycholate hydrate; taurodeoxycholic acid sodium salt monohydrate; Taurodeoxycholic acid sodium salt hydrate; MFCD00149238; Taurodeoxycholic acid (sodium hydrate); sodium;2-[[(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate;hydrate; SODIUM HYDRATE TAURODEOXYCHOLATE;

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

H2O: 100 mg/mL (191.68 mM)
DMSO: 100 mg/mL (191.68 mM)

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。